Communities of Practice in the Public-Private-Partnership Sector for Neglected Diseases Drug Development: the Importance of Mindset Mapping

C.J. Brown, P. Frame

Research output: Working paper

54 Downloads (Pure)

Abstract

This research article explores the mindsets of Public-Private Partnerships and Clinical Trials Organizations (CTOs) and the potential conflicts when working on drug discovery and development in the Third World global infectious diseases sector. A Communities-of-Practice (CoP) approach has been adopted to more fully explore the underlying values, attitudes and practices of these two future partners. This exploratory study suggests that future collaboration will be dependent on the two communities understanding and interpretation of each others‟ sustainability drug development drivers. The authors present secondary research findings that suggest the positive contribution that cognitive mapping of a community‟s sense-making can have in understanding the community‟s likely engagement in any future joint enterprise. Proposed future research will explore the underlying sustainability drivers that may both push and pull CTOs to engage in future global infectious diseases discovery and development projects. The article concludes by discussing the implications for future sustainable drug development projects involving PPPs and potential new strategic partners.
Original languageEnglish
PublisherUniversity of Hertfordshire
Publication statusPublished - 2009

Publication series

NameUH Business School Working Paper
PublisherUniversity of Hertfordshire

Fingerprint

Dive into the research topics of 'Communities of Practice in the Public-Private-Partnership Sector for Neglected Diseases Drug Development: the Importance of Mindset Mapping'. Together they form a unique fingerprint.

Cite this